Aaron Berg is recorded as Board Member at Amarin Corp Plcuk (AMRN) since June 4, 2024. Amarin Corp Plcuk reported in an 8-K filed July 29, 2024 that Aaron Berg was appointed member of the Company's board of directors, effective June 4, 2024. Amarin Corp Plcuk reported in an 8-K filed July 29, 2024 that Aaron Berg was appointed President and Chief Executive Officer, effective June 4, 2024. Amarin Corp Plcuk reported in an 8-K filed June 4, 2024 that Aaron Berg was appointed member of the Company's board of directors, effective June 4, 2024. Equibles holds 5 filed executive changes naming Aaron Berg; each is listed under recent activity with its source filing. Aaron Berg has spoken on 13 earnings calls across 1 company, most recently for Amarin Corp Plcuk on October 28, 2026. Amarin Corp Plcuk is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Amarin Corp Plcuk includes Aaron D. Berg (CEO), Patrick Holt (CEO and Board Member), Odysseas D. Kostas (Chairman) and 7 others.
“Mr. Berg was also appointed as a member of the Company's board of directors (the "Board"), effective as of the CEO Start Date.”
Amarin Corp Plcuk Form 8-K, filed July 29, 2024
· Read the filing
“Aaron Berg was appointed to the role of President and Chief Executive Officer (and principal executive officer) of the Company, effective June 4, 2024 (the "CEO Start Date").”
Amarin Corp Plcuk Form 8-K, filed July 29, 2024
· Read the filing
Aaron Berg on recent calls
“As we approach the end of the year, I want to take the opportunity to highlight all that we've achieved, what lies ahead, and most importantly, how we continue to hold ourselves accountable to the standard of delivering value to our shareholders.”
“Q2 2026 marked an inflection point for Ameren, highlighting the one-year anniversary of our dual commercial strategy that combines continued execution of our U.S. business with a fully partnered international commercial platform.”
“The momentum that started to build in late 2025 continued in the first quarter of 2026. Our results and cash generation in the quarter demonstrate our progress in advancing our new business model and expanding the global market for Resipa through our new and more efficient operating platform.”
“2025 was a year of substantial achievement for Ameren. The strategy we've been developing to transform our business model and expand the global market for our Vescepa-Vescepa franchise took shape and began producing measurable results.”
“My comments today will focus on 3 themes: what we've done to get to this point, how the business is operating today and most importantly, where we're going and why it's compelling as an opportunity for all our stakeholders.”
